DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hyperphosphatemia market report provides current treatment practices, emerging drugs, Hyperphosphatemia market share of the individual therapies, and current and forecasted Hyperphosphatemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hyperphosphatemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hyperphosphatemia market.
Some of the key facts of the Hyperphosphatemia Market Report:
The United States, in 2021, accounted for 484,792 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 55,742 in 2021. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,981 in 2021.
Got queries? Click here to know more about the Hyperphosphatemia Market Landscape
Hyperphosphatemia Overview
Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. Hyperphosphatemia does not usually have apparent symptoms. It is more likely that the symptoms of an underlying disease that can cause high phosphate levels, such as uncontrolled diabetes, are spotted first. More commonly, patients report uremic symptoms such as fatigue, shortness of breath, anorexia, nausea, vomiting, and sleep disturbances. If phosphate levels in the blood become too high, it may cause mineral and bone disorders and calcification. Also, hyperphosphatemia complexes serum calcium, decreasing the levels of ionized calcium and triggering PTH release, resulting in secondary hyperparathyroidism; this causes a high bone turnover state, releasing calcium from the bone to normalize the serum calcium level.
Treatment for the condition includes restriction of phosphate intake and administration of phosphate-binding antacids, such as calcium carbonate, which can help normalize the phosphate levels in the blood. Dietary modification or consuming a low-phosphorus diet is also necessary, especially in the case of kidney patients. FDA approved phosphate binder therapies for the treatment of the condition includes Kiklin, Auryxia/ Riona/ Nephoxil and Velphoro/ P-TOL. Hyperphosphatemia is often a complication of CKD. One way to reduce the risk is by slowing kidney damage, i.e. by protecting the kidneys by treating the cause of the kidney disease. Another way to reduce the risk is by eating certain foods and avoiding others. It is recommended that a person with an underlying condition linked to hyperphosphatemia should avoid food items that have the letters PHOS. Additionally, certain natural foods, such as peas, milk, and peanut butter, also contain high phosphorus levels. For people with kidney disease, eating a diet with the right amount of minerals is essential in managing the condition.
Hyperphosphatemia Epidemiology Insights
Hyperphosphatemia Market Epidemiology Segmentation
Hyperphosphatemia Market Market Outlook
The Hyperphosphatemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatemia market trends by analyzing the impact of current Hyperphosphatemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Hyperphosphatemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hyperphosphatemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hyperphosphatemia market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Hyperphosphatemia Market
Hyperphosphatemia Market Key Companies
Hyperphosphatemia Market Therapies
Table of Contents
Click here to read more about Hyperphosphatemia Market
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Adya KaulEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/